Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A successful technology transfer of a lentiviral (LV) vector process to a GMP manufacturing environment is predicated on a well-defined, data-rich process package. For UK-based therapeutic sponsors, aligning this package with both internal process development data and the specific requirements of the receiving organization is a frequent point of failure, leading to extended timelines and budget overruns. This overview provides a framework for de-risking LV tech transfer, focusing on process definition, analytical alignment, and regulatory documentation for MHRA submissions.

Defining a Transfer-Ready Lentiviral Process

The objective of a technology transfer is the reproducible execution of a manufacturing process at a different site. This begins with a process that is well-understood and documented. A standard template does not exist; the strategy must be tailored to the specific LV vector and its intended clinical application.

Key components of the transfer package include:

• A detailed, step-by-step process description with defined operating ranges.

• Complete specifications for all raw materials, including plasmids and cell banks.

• A comprehensive list of in-process controls (IPCs) with established acceptance criteria.

• Data from engineering or scale-down runs that characterize process performance.

Modifying viral envelopes to enhance gene transfer (PMID: 14599811) directly informs the manufacturing control strategy. A vector designed for higher efficiency may require different purification challenges or analytical release assays compared to a parental construct.

A collaborative approach, combining deep scientific expertise in both vector production and the associated analytical methods, is fundamental to de-risking the technology transfer process.

Analytical Method Transfer and Qualification

Analytical methods are the tools used to measure process performance and product quality. Transferring assays without a robust understanding of their performance characteristics is a primary source of risk. Each assay must be qualified in a phase-appropriate manner to demonstrate it is fit for purpose.

For UK and EU programs, this means ensuring the methods can generate the data required for IMPD submissions. This includes assays for vector identity, purity, quantity, and potency. The receiving organization must demonstrate proficiency with these methods before the process is implemented in their GxP environment.

Our >100,000 sq ft facility provides the infrastructure to develop and qualify these complex analytical methods alongside the manufacturing process. This integrated approach has been a component of achieving a 100% successful IND rate for associated programs since 2019, with the Franklin Biolabs brand formally launching in 2024 to expand these services to the broader industry.

Regulatory Alignment for MHRA Submissions

The ultimate goal of the tech transfer is to enable GMP manufacturing that supports clinical investigations. For UK-based sponsors, this means compiling a CMC data package that meets MHRA expectations. Proactive engagement and a clear understanding of regulatory requirements prevent late-stage delays.

The transfer process itself should be governed by a comprehensive plan that outlines deliverables, responsibilities, and timelines. This plan becomes a key document in demonstrating control over the manufacturing process to regulatory authorities. Seamless Tech Transfer Accelerating GMP Readiness.